WHO seeks use of masks as COVID-19 re-surges globally

The World Health Organisation has said nose masks continue to be a key tool against COVID-19 which must be used by the public in specific situations.

Vanguard reports that in a new update, WHO recommends use of masks irrespective of the local epidemiological situation, given the current spread of the COVID-19 globally.

The global health body said it was working with guideline development groups composed of independent, international experts who consider the latest available evidence and the changing epidemiology.

“Masks are recommended following a recent exposure to COVID-19, when someone has or suspects they have COVID-19, when someone is at high-risk of severe COVID-19, and for anyone in a crowded, enclosed, or poorly ventilated space.”

On isolation, WHO advises that a COVID-19 patient can be discharged from isolation early if they test negative on an antigen-based rapid test.

“Without testing, for patients with symptoms, the new guidelines suggest 10 days of isolation from the date of symptom onset. Previously, WHO advised that patients be discharged 10 days after symptom onset, plus at least three additional days since their symptoms had resolved.

For those who test positive for COVID-19 but do not have any signs or symptoms, WHO suggests five days of isolation in the absence of testing, compared to 10 days previously.

Isolation of people with COVID-19 is an important step in preventing others from being infected. This can be done at home or at a dedicated facility, such as a hospital or clinic.

The evidence considered by the guideline development group showed that people without symptoms are much less likely to transmit the virus than those with symptoms. Although of very low certainty, evidence also showed that people with symptoms discharged at day five following symptom onset risked infecting three times more people than those discharged at day 10.

In a review of COVID-19 treatment, the WHO extended its strong recommendation for the use of nirmatrelvir-ritonavir (Paxlovid).

Nirmatrelvir-ritonavir was first recommended by WHO in April 2022 and the agency strongly recommends its use in mild or moderate COVID-19 patients who are at high-risk of hospitalisation

WHO also reviewed the evidence on sotrovimab and casirivimab-imdevimab, and maintains strong recommendations against their use for treating COVID-19.

There are currently six proven treatment options for patients with COVID-19, three that prevent hospitalisation in high-risk persons and three that save lives in those with severe or critical disease. Except for corticosteroids, access to other drugs remains unsatisfactory globally.